Author

Neeraj Narula

WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS
WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS

Neeraj Narula  et al.

USTEKINUMAB IMPROVES EXTRA-INTESTINAL MANIFESTATIONS IN CROHN'S DISEASE: A POST HOC ANALYSIS OF THE UNITI STUDIES
USTEKINUMAB IMPROVES EXTRA-INTESTINAL MANIFESTATIONS IN CROHN'S DISEASE: A POST HOC ANALYSIS OF THE UNITI STUDIES

Neeraj Narula  et al.

PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC
PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC

Neeraj Narula  et al.

MEASUREMENT OF ULCERATED AND AFFECTED SURFACE OF THE COLON MAY PROVIDE MORE INSIGHT INTO RESPONSE COMPARED TO ENDOSCOPIC MAYO SCORE - A POST HOC ANALYSIS
MEASUREMENT OF ULCERATED AND AFFECTED SURFACE OF THE COLON MAY PROVIDE MORE INSIGHT INTO RESPONSE COMPARED TO ENDOSCOPIC MAYO SCORE - A POST HOC ANALYSIS

Neeraj Narula  et al.

USTEKINUMAB IMPROVES EXTRA-INTESTINAL MANIFESTATIONS IN CROHN'S DISEASE: A POST HOC ANALYSIS OF THE UNITI STUDIES
USTEKINUMAB IMPROVES EXTRA-INTESTINAL MANIFESTATIONS IN CROHN'S DISEASE: A POST HOC ANALYSIS OF THE UNITI STUDIES

Neeraj Narula

SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY
SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY

Neeraj Narula  et al.

SYSTEMATIC REVIEW AND META-ANALYSIS: SAFETY OF VEDOLIZUMAB DURING PREGNANCY IN FEMALE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SYSTEMATIC REVIEW AND META-ANALYSIS: SAFETY OF VEDOLIZUMAB DURING PREGNANCY IN FEMALE PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Neeraj Narula  et al.

BODY MASS INDEX DOES NOT IMPACT CLINICAL EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE IM-UNITI TRIAL
BODY MASS INDEX DOES NOT IMPACT CLINICAL EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE IM-UNITI TRIAL

Neeraj Narula  et al.

TREATMENT DISCONTINUATION FOR BIOSIMILAR VERSUS ORIGINATOR IN INFLIXIMAB INITIATORS
TREATMENT DISCONTINUATION FOR BIOSIMILAR VERSUS ORIGINATOR IN INFLIXIMAB INITIATORS

Neeraj Narula  et al.

EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Neeraj Narula  et al.

INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN’S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS
INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN’S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS

Neeraj Narula  et al.

Item 1 - 11 / 11
1